| Year |
Citation |
Score |
| 2022 |
Rawat V, Eastman CL, Amaradhi R, Banik A, Fender JS, Dingledine RJ, D'Ambrosio R, Ganesh T. Temporal Expression of Neuroinflammatory and Oxidative Stress Markers and Prostaglandin E2 Receptor EP2 Antagonist Effect in a Rat Model of Epileptogenesis. Acs Pharmacology & Translational Science. 6: 128-138. PMID 36654746 DOI: 10.1021/acsptsci.2c00189 |
0.722 |
|
| 2022 |
Varvel NH, Amaradhi R, Espinosa-Garcia C, Duddy S, Franklin R, Banik A, Alemán-Ruiz C, Blackmar-Raynolds L, Wang W, Honore T, Ganesh T, Dingledine R. Preclinical development of an EP2 antagonist for post-seizure cognitive deficits. Neuropharmacology. 224: 109356. PMID 36460083 DOI: 10.1016/j.neuropharm.2022.109356 |
0.655 |
|
| 2022 |
Amaradhi R, Mohammed S, Banik A, Franklin R, Dingledine R, Ganesh T. Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties. Acs Pharmacology & Translational Science. 5: 118-133. PMID 35187419 DOI: 10.1021/acsptsci.1c00255 |
0.732 |
|
| 2022 |
Rawat V, Banik A, Amaradhi R, Rojas A, Taval S, Nagy T, Dingledine R, Ganesh T. Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 147: 112646. PMID 35091236 DOI: 10.1016/j.biopha.2022.112646 |
0.701 |
|
| 2021 |
Banik A, Amaradhi R, Lee D, Sau M, Wang W, Dingledine R, Ganesh T. Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's disease. Journal of Neuroinflammation. 18: 273. PMID 34801055 DOI: 10.1186/s12974-021-02297-7 |
0.651 |
|
| 2021 |
Rojas A, Amaradhi R, Banik A, Jiang C, Abreu-Melon J, Wang S, Dingledine R, Ganesh T. A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33410110 DOI: 10.1007/s13311-020-00969-5 |
0.755 |
|
| 2020 |
Amaradhi R, Banik A, Mohammed S, Patro V, Rojas A, Wang W, Motati DR, Dingledine R, Ganesh T. Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models. Journal of Medicinal Chemistry. PMID 31904232 DOI: 10.1021/Acs.Jmedchem.9B01218 |
0.756 |
|
| 2019 |
Rojas A, Banik A, Chen D, Flood K, Ganesh T, Dingledine R. A novel microglia cell line expressing the human EP2 receptor. Acs Chemical Neuroscience. PMID 31469538 DOI: 10.1021/Acschemneuro.9B00311 |
0.727 |
|
| 2018 |
Ganesh T, Banik A, Dingledine R, Wang W, Amaradhi R. Peripherally restricted, highly potent, selective, aqueous-soluble EP2 antagonist with anti-inflammatory properties. Molecular Pharmaceutics. PMID 30398879 DOI: 10.1021/Acs.Molpharmaceut.8B00764 |
0.73 |
|
| Show low-probability matches. |